Vestal Point Capital LP Grows Position in Alto Neuroscience, Inc. (NYSE:ANRO)

Vestal Point Capital LP grew its stake in Alto Neuroscience, Inc. (NYSE:ANRO) by 4.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 650,000 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Vestal Point Capital LP owned approximately 2.41% of Alto Neuroscience worth $7,436,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. MetLife Investment Management LLC bought a new stake in shares of Alto Neuroscience during the 3rd quarter valued at $146,000. BNP Paribas Financial Markets increased its stake in Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after buying an additional 3,715 shares in the last quarter. FMR LLC raised its holdings in Alto Neuroscience by 1.4% during the third quarter. FMR LLC now owns 2,363,056 shares of the company’s stock valued at $27,033,000 after acquiring an additional 32,040 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Alto Neuroscience by 84.5% in the third quarter. The Manufacturers Life Insurance Company now owns 65,805 shares of the company’s stock valued at $753,000 after acquiring an additional 30,135 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Alto Neuroscience by 182.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock worth $2,139,000 after acquiring an additional 120,779 shares during the period.

Analyst Ratings Changes

A number of research firms recently commented on ANRO. RODMAN&RENSHAW cut Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Stifel Nicolaus dropped their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Finally, Robert W. Baird cut their price objective on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Alto Neuroscience Stock Performance

ANRO stock opened at $4.28 on Friday. Alto Neuroscience, Inc. has a 52 week low of $3.61 and a 52 week high of $24.00. The company has a fifty day simple moving average of $8.03 and a two-hundred day simple moving average of $10.69. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. Research analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.